MAP2K7 and melanoma: Inhibiting the MAPK pathway in BRAFV600-mutant melanoma patients with BRAF inhibitors (vemurafenib and dabrafenib) or a MEK inhibitor (trametinib) has improved progression-free and/or overall survival compared to conventional chemotherapy [7-10].